Contribution of the capsular polysaccharide layer to antibiotic resistance in bifidobacteria.


Journal

FEMS microbiology ecology
ISSN: 1574-6941
Titre abrégé: FEMS Microbiol Ecol
Pays: England
ID NLM: 8901229

Informations de publication

Date de publication:
23 03 2023
Historique:
received: 28 09 2022
revised: 23 02 2023
accepted: 17 03 2023
medline: 31 3 2023
pubmed: 21 3 2023
entrez: 20 3 2023
Statut: ppublish

Résumé

Bifidobacteria have been shown to produce exopolysaccharides (EPS), which are polymeric structures composed of various carbohydrates, commonly containing glucose, galactose, and rhamnose. EPS are produced by different bifidobacterial taxa commonly identified in the human gut, such as Bifidobacterium breve and Bifidobacterium longum subsp. longum, and have been suggested to modulate the interaction of bifidobacterial cells with other members of the human gut microbiota as well as with their host. In this study, we evaluated if bifidobacterial EPS production of four selected EPS-producing strains is associated with enhanced resistance to antibiotic treatments through MIC analysis when compared to bacterial cultures that do not produce exopolysaccharides. Our results showed that an increase in EPS production by modifying the growth medium with different carbon sources, i.e. glucose, galactose or lactose and/or by applying stressful conditions, such as bile salts and acidity, is associated with a tolerance enhancement of bifidobacterial cells toward various beta-lactam antibiotics. In addition, after analyzing the production of EPS at the phenotypic level, we explored the genes involved in the production of these structures and evaluated their expression, in presence of various carbon sources, using RNAseq. Overall, this study provides preliminary experimental evidence showing how bifidobacterial EPS modifies the level of susceptibility of these bacteria towards antibiotics.

Identifiants

pubmed: 36941125
pii: 7081306
doi: 10.1093/femsec/fiad032
pii:
doi:

Substances chimiques

Galactose X2RN3Q8DNE
Polysaccharides 0
Glucose IY9XDZ35W2
Anti-Bacterial Agents 0
Carbon 7440-44-0

Types de publication

Journal Article Research Support, Non-U.S. Gov't

Langues

eng

Sous-ensembles de citation

IM

Informations de copyright

© The Author(s) 2023. Published by Oxford University Press on behalf of FEMS.

Auteurs

Chiara Argentini (C)

Laboratory of Probiogenomics, Department of Chemistry, Life Sciences and Environmental Sustainability, University of Parma, Parma, 43124, Italy.

Chiara Tarracchini (C)

Laboratory of Probiogenomics, Department of Chemistry, Life Sciences and Environmental Sustainability, University of Parma, Parma, 43124, Italy.

Giulia Alessandri (G)

Laboratory of Probiogenomics, Department of Chemistry, Life Sciences and Environmental Sustainability, University of Parma, Parma, 43124, Italy.

Giulia Longhi (G)

Laboratory of Probiogenomics, Department of Chemistry, Life Sciences and Environmental Sustainability, University of Parma, Parma, 43124, Italy.
GenProbio srl, 43124 Parma, Italy.

Christian Milani (C)

Laboratory of Probiogenomics, Department of Chemistry, Life Sciences and Environmental Sustainability, University of Parma, Parma, 43124, Italy.
Interdepartmental Research Centre "Microbiome Research Hub", University of Parma, 43124 Parma, Italy.

Douwe van Sinderen (D)

APC Microbiome Institute and School of Microbiology, Bioscience Institute, National University of Ireland, Cork, Ireland.

Marco Ventura (M)

Laboratory of Probiogenomics, Department of Chemistry, Life Sciences and Environmental Sustainability, University of Parma, Parma, 43124, Italy.
Interdepartmental Research Centre "Microbiome Research Hub", University of Parma, 43124 Parma, Italy.

Francesca Turroni (F)

Laboratory of Probiogenomics, Department of Chemistry, Life Sciences and Environmental Sustainability, University of Parma, Parma, 43124, Italy.
Interdepartmental Research Centre "Microbiome Research Hub", University of Parma, 43124 Parma, Italy.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH